Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

INTRODUCTION: Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited and CRE infections remain associated with high clinical failure and mortality rates, particularly in vulnerable patient populations. A Phase 3, multinational, open-label, randomized controlled tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wunderink, Richard G., Giamarellos-Bourboulis, Evangelos J., Rahav, Galia, Mathers, Amy J., Bassetti, Matteo, Vazquez, Jose, Cornely, Oliver A., Solomkin, Joseph, Bhowmick, Tanaya, Bishara, Jihad, Daikos, George L., Felton, Tim, Furst, Maria Jose Lopez, Kwak, Eun Jeong, Menichetti, Francesco, Oren, Ilana, Alexander, Elizabeth L., Griffith, David, Lomovskaya, Olga, Loutit, Jeffery, Zhang, Shu, Dudley, Michael N., Kaye, Keith S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249182/
https://www.ncbi.nlm.nih.gov/pubmed/30270406
http://dx.doi.org/10.1007/s40121-018-0214-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249182/
https://www.ncbi.nlm.nih.gov/pubmed/30270406
http://dx.doi.org/10.1007/s40121-018-0214-1

Ejemplares similares